Company profile
10x Genomics, Inc.
NASDAQ: TXG · Healthcare · Medical - Healthcare Information Services
#192 of 1,422 Healthcare companies by revenue49th-percentile growth
EA Score
67BFH 76DQ 58GM 57SS 71
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$638.8M
Rev growth YoY (TTM)
+2.3%
Net income (FY)
-$43.5M
Employees
1,178
as of 2026-08-07
Market cap
$5.8B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$642.8M$642.8M2025
Net income-$43.5M-$43.5M2025
Operating income-$61.0M-$61.0M2025
Total assets$1.0B$1.0B2025
Liabilities$245.0M$245.0M2025
Equity$796.3M$796.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product And Service Revenue48%
Consumables41%
Instruments5%
Licensing And Royalty Revenue4%
Service3%
By geography
Americas36%
UNITED STATES35%
EMEA16%
CHINA7%
Asia-Pacific, Excluding China5%
The read
What is 10x Genomics, Inc.’s revenue?
10x Genomics, Inc. booked $642.8M in FY2025 revenue, growing 5.2% year over year — about the middle of the pack among Healthcare companies we track, at a -6.8% net margin.
Peers · Healthcare
Ultragenyx Pharmaceutical Inc.58CCresco Labs Inc.37DDoximity, Inc.73BAxsome Therapeutics, Inc.59CTG Therapeutics, Inc.72BOPKO Health, Inc.74BNeighbors
Alameda →Key facts
CEOSerge Saxonov
SectorHealthcare
IndustryMedical - Healthcare Information Services
HeadquartersPleasanton, CA
ExchangeNASDAQ: TXG
Employees1,178
IPO date2019-09-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.